Organon & Co. (OGN) exhibits 53.3% gross margins and 24.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 19.4x enterprise multiple and 4.8% implied options volatility.
Sustained 53.3% gross profitability converts into — operating margin and 24.9% ROIC, outpacing sector cost of capital.
ROIC: 24.9% // GM: 53.3%YoY revenue trajectory of -2.9% paired with 14.83% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -2.9% // FCF YLD: 14.83%Altman Z-Score of 3.80 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.80 // F-SCORE: 6/9Trading at 19.4x trailing P/E (18.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 19.4x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $13.81 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 3.0% net margins.
NET MARGIN: 3.0% // D/E: 8.50x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for OGN & activate live FRED threshold breach alerts.